Delcath Systems Reports Q3 2026 Revenue Growth of 71% Driven by Hepzato Kit
Delcath Systems (DCTH) reported strong third-quarter 2026 financial results, highlighted by a 71% year-over-year increase in total revenue to $35.1 million. The growth was primarily driven by the Hepzato kit, which generated $32.7 million due to increased treatment volumes. The company also achieved significant profitability milestones, reporting a net income of $7 million and non-GAAP adjusted EBITDA of $11.5 million, up from $5.3 million in the prior year. Reflecting strong commercial momentum, management raised its full-year revenue guidance to between $115 million and $117 million. While the company is expanding its footprint with 33 active treatment centers in the U.S., leadership noted some headwinds, including slower enrollment in the breast cancer trial and potential holiday-related delays in Q4. Despite these risks, Delcath maintains a strong balance sheet with $104.3 million in cash and no debt.
Tickers: $DCTH
Topics: EBITDA Financial Results Guidance Upgrade Net Income Revenue Growth
Read the full article at Motley Fool
Part of the story Artmarket.com Announces Q3 2026 Revenue Growth and Upcoming Launch of AI-Driven Visual Search Tool (35 articles)